1. What is ASSURE-100?
ASSURE-100 is a rapid COVID-19 test that uses an anterior nasal specimen to detect COVID-19, the disease caused by the SARS-CoV-2 virus. ASSURE is an acronym for: Accelerated Sensor Solution for Urgent Response to Epidemics.
2. Where was ASSURE-100 developed?
The ASSURE technology and ASSURE-100 rapid COVID-19 test was developed by Oceanit in Hawaiʻi and was put through testing and clinical trials in Hawaii and in other states across the US.
3. How do ASSURE tests work?
ASSURE-100 uses shallow nasal specimens to detect COVID-19 using a lateral flow assay (LFA) test cassette. A shallow anterior nasal swab specimen is mixed with buffer solution and then poured into the well on the test cassette. ASSURE tests are visually read, and do not require an external device to interpret results.
4. Does ASSURE-100 Rapid COVID-19 Home Test detect Omicron variants?
Yes, the ASSURE-100 Rapid COVID-19 Home Test clinical trial included BA.2.12.1 and BA.2 variant samples. Additionally, the ASSURE-100 test was evaluated in a dilution series of clinical specimens positive for the Omicron variants BA.5 and BE.1. This testing was conducted by National Institutes of Health (NIH) as a component of the Rapid Acceleration of Diagnostics (RADx) initiative. Results indicate that ASSURE-100 detects both BA.5 and BE.1 variants.
5. How quickly will ASSURE-100 detect a result if positive?
Results should be read at 20 minutes.